Nefazodone
| 證據等級: L5 | 預測適應症: 2 個 |
目錄
Nefazodone: From Depression to Migraine Disorder
One-Sentence Summary
Nefazodone is a serotonin antagonist and reuptake inhibitor (SARI-class), historically used as an antidepressant. The TxGNN model predicts potential efficacy for Migraine Disorder (score 99.60%), but this is currently supported only by 3 narrative review articles and no dedicated clinical trials — the evidence is mechanistic/hypothesis-level, not clinically validated.
Note on original indication: This evidence pack does not contain confirmed original-indication or MOA data for nefazodone (flagged as data gaps DG001/DG002 below). “Depression” reflects the drug’s known SARI pharmacological class as referenced in the repurposing rationale, not a sourced field in this pack.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Depression (inferred from SARI drug class; not independently confirmed in this evidence pack) |
| Predicted New Indication | Migraine Disorder |
| TxGNN Prediction Score | 99.60% |
| Evidence Level | L4 (mechanism/literature-level, no dedicated clinical trials) |
| Taiwan (TFDA) Market Status | 未上市 (Not Marketed) |
| Number of TFDA Licenses | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism-of-action data for nefazodone is currently a data gap (DG002) in this evidence pack. Based on the repurposing rationale available, nefazodone is described as a 5-HT2A receptor antagonist combined with weak serotonin/norepinephrine reuptake inhibition (SARI class).
Serotonergic modulation has pharmacological plausibility in migraine prevention — other antidepressant classes (TCAs, SNRIs) already carry migraine-prophylaxis indications as precedent. However, this link is a mechanistic inference rather than direct clinical evidence specific to nefazodone. The TxGNN score of 0.996 reflects knowledge-graph similarity between nefazodone and other drugs/diseases in the graph, not clinical validation.
A secondary, lower-confidence prediction — migraine with brainstem aura (score 99.60%, evidence level L5, no supporting literature at all) — shares the same serotonergic rationale but lacks even review-level literature support, and involves brainstem-specific vascular/neural mechanisms not addressed by any available data.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 15926007 | 2005 | Review | Neurological Sciences | Overview of emerging migraine preventive treatment options; nefazodone discussed among candidate agents. |
| 15115635 | 2004 | Review | Current Pain and Headache Reports | Reviews prophylactic migraine therapies including topiramate, tizanidine, and nefazodone; overview of migraine pathophysiology. |
| 15549532 | 2004 | Review | Neurological Sciences | Reviews new preventive migraine drugs; notes evidence quality varies from controlled trials to open/uncontrolled studies. |
All three are narrative reviews (Tier 3) that mention nefazodone alongside multiple other agents — none are nefazodone-specific efficacy studies.
US Market Information
Nefazodone is not marketed in Taiwan (0 TFDA licenses on record); no license or approved-indication data is available in this evidence pack.
Safety Considerations
Please refer to the package insert for safety information. (Key warnings, contraindications, and DDI data are all unavailable in this evidence pack — TFDA label data is a Blocking data gap, DG001.)
Conclusion and Next Steps
Decision: Hold
Rationale: Evidence for migraine disorder is limited to three narrative reviews with no dedicated clinical trials, and the TFDA safety profile (warnings/contraindications) is entirely unavailable — this blocks any S1 safety pre-assessment. The secondary candidate (migraine with brainstem aura) has even weaker support (L5, no literature) and should remain deprioritized.
To proceed, the following is needed:
- TFDA package insert (warnings/contraindications) — resolve DG001 before any safety pre-assessment
- Confirmed MOA and original indication data from DrugBank — resolve DG002
- Dedicated clinical trial or case-series evidence specific to nefazodone in migraine prevention (current literature only mentions it in passing within broader reviews)
- DDI data, given nefazodone’s known hepatic metabolism-related interaction profile is currently unqueried (query_status: not_found)
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.